New FDA approval for Anakinra API for the Treatment of NOMID

New FDA approval for Anakinra API for the Treatment of NOMID

AnakinraOn January 8, 2012, the FDA has approved Anakinra, known as the brand name Kineret, to treat both adults and children with neonatal-onset multisystem inflammatory disease, or NOMID. Five years of data demonstrated that Anakinra is effectual at controlling the daily symptoms of NOMID, which include joint pain, headache, rash and fevers. In addition to offering relief from the debilitating symptoms of NOMID studies also showed that administration of this medication helped to stabilize integral central nervous system functions for patients, particularly hearing and vision. Certain cases of NOMID cause severe symptoms, like headaches, seizures and vomiting which result from chronic meningitis. Intellectual disabilities may also occur in some people with this NOMID.

interleukin antagonistIn a class of medications called interleukin antagonists Anakinra is  efficacious at blocking the activity of interleukin, which is a protein in the body that elicits joint damage. Dosage of Anakinra is available as a subcutaneous injection, to be administered once daily at the same time. Prefilled glass syringes are offered for patients, with 7 syringes, or one for each day of the week. Most patients see significant improvement in their symptoms within four weeks’ time. Adverse effects of Anakinra are uncommon, and may include headache, nausea and stomach pain. The news from the FDA approving Anakinra for the treatment of neonatal-onset multisystem inflammatory disease has created hope from the patients suffering from this genetic disorder. The mutations in the NLRP3 gene are the cause of this disorder for patients, and symptoms like a recurring rash and joint and tissue inflammation are present from birth in the majority of patients.

LGM Pharma offers API Anakinra CAS# 143090-92-0 for research and development purposes. Clients can be assured of quality products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: